Legal & General Group
KRYS icon

Legal & General Group’s Krystal Biotech KRYS Stock Holding History

Legal & General Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8M Sell
58,580
-470
-0.8% -$140K ﹤0.01% 846
2026
Q1 		$15.3M Sell
59,050
-4,311
-7% -$1.15M ﹤0.01% 931
2025
Q4 		$15.6M Sell
63,361
-2,454
-4% -$517K ﹤0.01% 950
2025
Q3 		$11.6M Sell
65,815
-2,578
-4% -$386K ﹤0.01% 1124
2025
Q2 		$9.4M Buy
68,393
+1,884
+3% +$277K ﹤0.01% 1224
2025
Q1 		$12M Sell
66,509
-2,916
-4% -$490K ﹤0.01% 1046
2024
Q4 		$10.9M Buy
69,425
+3,170
+5% +$562K ﹤0.01% 1121
2024
Q3 		$12.1M Buy
66,255
+1,666
+3% +$321K ﹤0.01% 1072
2024
Q2 		$11.9M Buy
64,589
+45,039
+230% +$7.56M ﹤0.01% 1040
2024
Q1 		$3.48M Buy
19,550
+458
+2% +$63.6K ﹤0.01% 1689
2023
Q4 		$2.37M Sell
19,092
-435
-2% -$48.2K ﹤0.01% 1867
2023
Q3 		$2.27M Buy
19,527
+821
+4% +$100K ﹤0.01% 1846
2023
Q2 		$2.2M Buy
18,706
+9,457
+102% +$966K ﹤0.01% 1886
2023
Q1 		$740K Buy
9,249
+2,129
+30% +$167K ﹤0.01% 2223
2022
Q4 		$564K Buy
7,120
+155
+2% +$11.5K ﹤0.01% 2305
2022
Q3 		$485K Buy
6,965
+387
+6% +$28K ﹤0.01% 2357
2022
Q2 		$431K Buy
6,578
+45
+0.7% +$2.8K ﹤0.01% 2380
2022
Q1 		$435K Buy
6,533
+370
+6% +$23.1K ﹤0.01% 2432
2021
Q4 		$432K Buy
6,163
+568
+10% +$33.1K ﹤0.01% 2457
2021
Q3 		$293K Buy
5,595
+2,816
+101% +$167K ﹤0.01% 2573
2021
Q2 		$189K Buy
2,779
+109
+4% +$7.61K ﹤0.01% 2547
2021
Q1 		$206K Buy
2,670
+281
+12% +$20.4K ﹤0.01% 2450
2020
Q4 		$144K Hold
2,389
– – ﹤0.01% 2487
2020
Q3 		$102K Sell
2,389
-355
-13% -$15.4K ﹤0.01% 2483
2020
Q2 		$113K Buy
2,744
+273
+11% +$13.1K ﹤0.01% 2494
2020
Q1 		$107K Sell
2,471
-469
-16% -$24.5K ﹤0.01% 2391
2019
Q4 		$163K Buy
2,940
+414
+16% +$20.3K ﹤0.01% 2448
2019
Q3 		$88K Buy
2,526
+1,066
+73% +$47.7K ﹤0.01% 2562
2019
Q2 		$59K Buy
+1,460
New +$47.7K ﹤0.01% 2705

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Legal & General Group's KRYS Position: Q2 2026 in Review

Legal & General Group reduced its Krystal Biotech (KRYS) stake by 0.8% in Q2 2026, selling an estimated $140K and leaving 58,580 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Legal & General Group first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Legal & General Group held 58,580 shares of Krystal Biotech worth $21.8M as of Q2 2026.
  • Legal & General Group sold 470 Krystal Biotech shares in Q2 2026, an estimated $140K.
  • Krystal Biotech made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #846 holding.
  • Legal & General Group first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.